Ann: Midkine Symposium Munich, page-23

Thanks @Pharmargeddon and @mightypirate for your links to Mk related and relevant articles both of which are squarely in the companies area of interest.

Whilst we are eagerly awaiting the outcomes of the ramping up on the Advandgen sales and potentially new distribution agreements, it is disappointing that there "appears" to be less eagerness and energy placed into Lyramid and Kinera.  Is it simply a case of keeping the cards close in a competitive Biotech environment or is there a passive "wait to be contacted " approach.    Isn't the 4 year CellmidZoetis agreement about to conclude. The CEO previously stated that in the absence of any notification all partnerships remain extant and ongoing.  So will we see an announcement in this area in the coming months. What about the QuestLicense update ? Is this test still being developed ?

I trust there may be more detail available at the general meeting this friday.